Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
BLUE BELL, Pa., Sept. 6, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has expanded its scientific advisory board with the appointment of two prominent leaders in the fields of vaccines and cancer immunotherapeutics. Joining Inovio's advisory board are Dr. Thomas S. Edgington, Emeritus Professor of the Scripps Research Institute and founder of several biotechnology companies; and Dr. Philip D. Greenberg, Professor of Medicine (Oncology) and Immunology, Department of Medicine, University of Washington.
Dr. Thomas S. Edgington is an emeritus professor of the Scripps Research Institute. Dr. Edgington served as the president and a board member of the Federation of American Societies for Experimental Biology (FASEB). He was founder and Chairman of the Board of Directors of Corvas International, Inc., which was acquired by Dendreon. Dr. Edgington also founded Molecular Biology Consultants Inc., BioSequences Ltd. and NuVas LLC. He served as a director of Apollon, one of the earliest DNA vaccine companies, which was acquired by Wyeth. He served as a member of the scientific advisory board of Halozyme Therapeutics, Inc. Dr. Edgington is a member of the U.S. National Academy of Sciences and the Institute of Medicine. He has over 500 publications in the biomedical sciences and filed over 25 patents.
Dr. Philip D. Greenberg is Professor of Medicine (Oncology) and Immunology, Department of Medicine, University of Washington and heads the Program in Immunology at the Fred Hutchinson Cancer Research Center. Dr. Greenberg has had a long-standing research career elucidating the principles that underlie T-cell recognition of viruses and cancer cells, determining why such responses often fail to eliminate the viral pathogen or cancer, and developi